Over the past few years, Big Pharma has experienced shrinking EBIT (earnings before interest and taxes) margins. The reasons behind this development are internal as well as external.
Internal reasons include the well-known patent-cliff, with many of the industry’s top revenue drivers losing exclusivity. In addition, Big Pharma...